Two Sigma Advisers LP grew its position in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 48.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 755,260 shares of the medical equipment provider's stock after acquiring an additional 246,800 shares during the quarter. Two Sigma Advisers LP owned about 0.05% of Boston Scientific worth $67,460,000 as of its most recent filing with the SEC.
Several other institutional investors have also modified their holdings of BSX. Temasek Holdings Private Ltd bought a new stake in Boston Scientific during the 4th quarter valued at $36,308,000. Tidal Investments LLC lifted its stake in shares of Boston Scientific by 38.6% in the 4th quarter. Tidal Investments LLC now owns 119,876 shares of the medical equipment provider's stock worth $10,707,000 after acquiring an additional 33,369 shares during the period. State of Wyoming boosted its holdings in shares of Boston Scientific by 119.5% in the fourth quarter. State of Wyoming now owns 2,660 shares of the medical equipment provider's stock valued at $238,000 after acquiring an additional 1,448 shares in the last quarter. Tema Etfs LLC acquired a new position in shares of Boston Scientific during the fourth quarter valued at approximately $1,831,000. Finally, Toronto Dominion Bank raised its holdings in Boston Scientific by 8.2% during the fourth quarter. Toronto Dominion Bank now owns 803,749 shares of the medical equipment provider's stock worth $71,790,000 after purchasing an additional 60,822 shares in the last quarter. Institutional investors own 89.07% of the company's stock.
Insider Buying and Selling
In related news, CEO Michael F. Mahoney sold 164,443 shares of the firm's stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $102.48, for a total value of $16,852,118.64. Following the completion of the transaction, the chief executive officer now owns 1,535,706 shares of the company's stock, valued at approximately $157,379,150.88. This trade represents a 9.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Vance R. Brown sold 4,826 shares of the business's stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $95.09, for a total transaction of $458,904.34. Following the sale, the senior vice president now directly owns 36,193 shares in the company, valued at $3,441,592.37. This trade represents a 11.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 263,163 shares of company stock worth $27,129,540. 0.50% of the stock is owned by corporate insiders.
Boston Scientific Stock Performance
Shares of Boston Scientific stock opened at $106.61 on Tuesday. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. The firm has a 50 day simple moving average of $99.39 and a 200 day simple moving average of $96.90. Boston Scientific Co. has a fifty-two week low of $71.88 and a fifty-two week high of $107.36. The firm has a market cap of $157.72 billion, a P/E ratio of 85.29, a P/E/G ratio of 2.79 and a beta of 0.68.
Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.67 by $0.08. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. The firm had revenue of $4.66 billion for the quarter, compared to analysts' expectations of $4.57 billion. During the same quarter last year, the business earned $0.56 earnings per share. The company's revenue was up 20.9% compared to the same quarter last year. Sell-side analysts predict that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of analysts have recently commented on BSX shares. Barclays boosted their price objective on Boston Scientific from $118.00 to $125.00 and gave the stock an "overweight" rating in a research note on Friday, April 25th. Wells Fargo & Company boosted their price target on shares of Boston Scientific from $100.00 to $118.00 and gave the stock an "overweight" rating in a research report on Thursday, February 6th. Stifel Nicolaus lifted their price objective on shares of Boston Scientific from $100.00 to $115.00 and gave the stock a "buy" rating in a research note on Thursday, February 6th. Erste Group Bank raised shares of Boston Scientific to a "strong-buy" rating in a research note on Thursday, May 8th. Finally, Piper Sandler lifted their price target on shares of Boston Scientific from $95.00 to $115.00 and gave the stock an "overweight" rating in a research report on Monday, February 3rd. Twenty-three research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $114.74.
Read Our Latest Research Report on BSX
Boston Scientific Profile
(
Free Report)
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Boston Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Boston Scientific wasn't on the list.
While Boston Scientific currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
